A quiet but explosive moment just happened in the peptide world.
Andrew Huberman weighed in on the growing conversation around peptides, randomized controlled trials, and regulatory limitations. His takeaway was familiar to anyone paying close attention: the science is promising, but large-scale RCTs have been limited and likely will remain
